MedPath

1,2-Distearoyllecithin

Generic Name
1,2-Distearoyllecithin
Brand Names
Lumason
Drug Type
Small Molecule
Chemical Formula
C44H88NO8P
CAS Number
4539-70-2
Unique Ingredient Identifier
EAG959U971

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Sep 30, 2025

An In-Depth Analysis of 1,2-Distearoylphosphatidylcholine (DSPC): From Physicochemical Properties to Advanced Pharmaceutical Applications

Executive Summary

1,2-Distearoylphosphatidylcholine (DSPC) is a fully saturated, synthetic phospholipid that has emerged as an indispensable excipient in the field of advanced drug delivery. While its primary role is to serve as a structural component in lipid-based nanocarriers, such as liposomes and lipid nanoparticles (LNPs), its function extends far beyond that of an inert scaffold. This report provides a comprehensive analysis of DSPC, synthesizing data on its chemical identity, physicochemical characteristics, pharmacological activity, and regulatory standing to present a holistic view of its significance in modern medicine.

The defining feature of DSPC is its high main phase transition temperature () of approximately 55°C. This property ensures that at physiological temperature (37°C), DSPC-based lipid bilayers exist in a highly ordered, rigid "gel" phase. This physical state confers exceptional structural stability and low permeability to drug delivery systems, minimizing premature drug leakage and extending the shelf-life of pharmaceutical products. These characteristics have made DSPC a cornerstone lipid in formulations requiring long systemic circulation times and controlled release kinetics. Its utility is exemplified by its inclusion in several clinically approved products, most notably as a critical structural component in the LNP formulations for the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines, where it provides the necessary stability to protect the fragile mRNA payload.

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/09/19
Phase 1
Not yet recruiting
2024/05/06
Phase 3
Not yet recruiting
2024/03/26
Phase 1
Not yet recruiting
2023/07/24
Early Phase 1
Recruiting
2022/11/14
Phase 1
Completed
2022/10/06
Phase 1
Recruiting
2021/01/22
Phase 1
Completed
2020/09/30
Phase 4
Completed
2019/05/17
Early Phase 1
Completed
2018/08/31
Phase 1
Not yet recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.